Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India

Arshdeep Singh; Mayur Luthra; Arshia Bhardwaj; Ramit Mahajan; Riya Sharma; Dharmatma Singh; Devanshi Jain; Omesh Goyal; Varun Mehta; Kirandeep Kaur; Yogesh Kumar Gupta; Vandana Midha; Ajit Sood

doi:10.5217/ir.2024.00189

Articles

Page Path: HOME > Intest Res > Ahead-of print articles > Article

Original Article Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India: Arshdeep Singh¹, Mayur Luthra¹, Arshia Bhardwaj¹, Ramit Mahajan¹, Riya Sharma², Dharmatma Singh¹, Devanshi Jain³, Omesh Goyal¹, Varun Mehta¹, Kirandeep Kaur⁴, Yogesh Kumar Gupta¹, Vandana Midha^5,, Ajit Sood^1,; DOI: https://doi.org/10.5217/ir.2024.00189
Published online: June 9, 2025

¹Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India

²Digestive Diseases Care Foundation, Ludhiana, India

³Research and Development Centre, Dayanand Medical College and Hospital, Ludhiana, India

⁴Department of Pharmacology, Dayanand Medical College and Hospital, Ludhiana, India

⁵Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, India

Correspondence to Ajit Sood, Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab 141001, India. E-mail: dr_ajit_sood@dmch.edu

Co-Correspondence to Vandana Midha, Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, Punjab 141001, India. E-mail: vandana_midha2@yahoo.co.in

• Received: November 18, 2024 • Revised: January 29, 2025 • Accepted: March 4, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

270 Views
29 Download

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
Supplementary Material
REFERENCES

Abstract

Background/Aims
Acute severe ulcerative colitis (ASUC) is a time-critical situation requiring urgent intervention. Limited data exist on the evolving clinical spectrum of ASUC in the era of advanced therapies.
Methods
This prospective real-world observational cohort study included 145 adult patients hospitalized with ASUC between January 2020 and June 2024. ASUC was defined by the modified Truelove and Witts criteria. Demographics and disease characteristics, including disease severity, probable precipitating factors, and corticosteroid failure rates, were recorded.
Results
The median age of patients was 36 years (interquartile range, 26–48.5 years) with 63 females (43.4%). Most patients had left-sided colitis (53.1%). The median disease duration was 1 year (IQR, 0.5–3 years), with 91 patients (62.7%) presenting with ASUC within the first year of diagnosis of ulcerative colitis. One-third of the patients had previous exposure to biologics and small molecules. The most commonly reported probable precipitants of ASUC were poor compliance with treatment (n = 43, 29.6%), antibiotic use (n = 35, 24.1%), high perceived stress (n = 32, 22.1%), and Clostridioides difficile infection (n = 19, 13.1%). Forty patients (27.5%) were non-responders to intravenous corticosteroids (IVCS). Twenty-nine patients (20%) received medical rescue therapy (infliximab, n = 14 [48.27%], cyclosporine A, n = 6 [20.68%], and tofacitinib, n = 9 [31.03%]). Seven patients (4.82%; 4 after non-response to IVCS and 3 after non-response to medical rescue therapy) underwent colectomy.
Conclusions
In this cohort of ASUC patients, poor treatment compliance, antibiotic use, stress, and C. difficile infection were common precipitants of flare-ups. Nearly one-third of patients required medical rescue therapy, and a small proportion ultimately underwent colectomy.
Keywords: Corticosteroids; Precipitating factors; Profile; Spectrum; Ulcerative colitis

INTRODUCTION

Acute severe ulcerative colitis (ASUC) is the most severe form of ulcerative colitis and necessitates urgent medical intervention. ASUC is associated with significant morbidity and mortality, and approximately 1 in 5 patients ultimately require colectomy [1]. Despite advancements in therapeutic strategies, including the use of immunosuppressants, biologics, and/or small molecules, the outcomes for ASUC have remained largely unchanged over recent decades [2]. This stagnation in outcomes highlights the need for a deeper understanding of the factors associated with disease behavior. While recent studies have primarily focused on the therapeutic interventions in ASUC, there is a notable lack of data on the clinical spectrum of the disease, warranting a comprehensive re-evaluation. Given the evolution in disease management and the widespread use of immunosuppressive agents and advanced therapies, it is expected that the clinical profile of ASUC has shifted over time. Therefore, revisiting the current disease spectrum is essential to understanding how these shifts may affect patient outcomes.

We aimed to evaluate the clinical profile of ASUC, including patient demographics, disease characteristics, potential triggers for disease exacerbation, responses to intravenous corticosteroids (IVCS), and the performance of the predictive indices.

METHODS

1. Study Design

This prospective real-world observational cohort study was conducted in patients with ASUC admitted to the Department of Gastroenterology at Dayanand Medical College and Hospital, India, between January 2020 and June 2024. The study was approved by the Institutional Ethics Committee of Dayanand Medical College and Hospital (DMCH/R&D/IEC/2020/23). Informed consent was obtained from all the participants.

2. Study Population

Consecutive adult patients ( ≥ 18 years of age) who were hospitalized due to ASUC were included. ASUC was defined by the modified Truelove and Witts (TW) criteria ( ≥ 6 stools with blood and at least one of the following: pulse >90 beats per minute, temperature >37.8°C, hemoglobin <10.5 g/dL, and C-reactive protein [CRP] >30 mg/L) [3]. Patients with severe ulcerative colitis (UC) not fulfilling the TW criteria, infectious or indeterminate colitis, toxic megacolon, and intestinal perforation, or massive hemorrhage requiring emergency colectomy, and those enrolled in the TACOS trial were excluded [4].

3. Data Collection

A structured questionnaire was developed to systematically capture comprehensive information relevant to the study. The sections of the questionnaire included demographics, disease activity, nutritional status, probable precipitants of acute exacerbation, treatment, and clinical outcomes.

1) Demographic Data and Clinical Profile

The patient demographics (including age and sex) and clinical characteristics (including age at diagnosis, disease duration and extent, disease activity, and previous treatment) were recorded at the time of hospitalization. The investigations, including hemogram, liver and renal function tests, CRP, and a limited unprepared flexible sigmoidoscopy with biopsy for histopathology, were performed in all patients within 24 hours of hospitalization.

2) Assessment of Disease Activity

The endoscopic disease severity was assessed by the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) [5]. The score (0–8) is calculated by the sum of 3 descriptors, including vascular pattern (scored 0–2), bleeding (scored 0–3), and erosions and ulcers (scored 0–3) assessed at the most severely affected area on flexible sigmoidoscopy. The number of additional TW criteria (including tachycardia, temperature, hemoglobin and CRP [1 point for each criterion]); admission model for intensification of therapy in acute severe colitis (ADMITASC; which includes albumin <2.5g/dL [1 point], CRP >100 mg/L [1 point], UCEIS ≥ 4 [1 point] or UCEIS ≥ 7 [2 points]); albumin, CRP, and endoscopy (ACE) index (including albumin <3 g/dL, CRP >50 mg/L and severe endoscopic lesions [1 point for each criterion]) and ASUC score (admission steroid use, serum albumin and endoscopic severity [1 point for each criterion]) were calculated for all patients [6-8].

3) Nutritional Assessment

All patients underwent nutritional screening and assessment at presentation. The malnutrition universal screening tool (MUST) was used to screen for malnutrition and a score ≥2 was taken as high risk of malnutrition. For nutritional assessment, anthropometric measurements including height, body weight, body mass index and handgrip strength (Jamar hydraulic hand dynamometer) were noted.

4) Precipitants of ASUC

For all patients, the probable precipitating factors for ASUC were recorded. Broadly, the precipitating factors were grouped into infectious and non-infectious causes. These factors were pre-defined and included presence or consumption of any of the following within 4 weeks preceding hospitalization:

(1) Infectious causes

• Enteric infections

- Stool routine examination and culture: All patients underwent stool routine examination and stool culture to identify potential infectious agents. Routine examination included microscopy for ova, cysts, and parasites, while culture targeted enteric pathogens.

- Clostridioides difficile infection (CDI): Stool samples were tested for glutamate dehydrogenase (GDH), toxin A, and toxin B using the Vitassay rapid kit. CDI was confirmed in cases with a positive GDH result accompanied by a positive result for either toxin A or toxin B. If GDH was positive but both toxin A and toxin B were negative, a stool polymerase chain reaction for CDI was performed. A positive polymerase chain reaction result was considered diagnostic for CDI.

- Cytomegalovirus: Histological evaluation included hematoxylin and eosin-stained biopsy samples to identify owl’s eye inclusion bodies, along with immunohistochemistry for all patients. The presence of cytomegalovirus was diagnosed upon identification of inclusion bodies or a positive immunohistochemistry result.

• Extra-enteric infections: For patients with suspected extraintestinal infections, relevant diagnostic investigations were conducted, including body fluid cultures and specific tests based on the suspected infectious etiology.

(2) Non-infectious causes

• Compliance to therapy: This was evaluated using the Medication Adherence Rating Scale (MARS-5). This scale includes five items scored from 1 to 5, with a total score range of 5–25. Non-compliance to therapy was defined as a MARS-5 score of ≤ 15, indicating suboptimal adherence to prescribed medications [9].

• Medication use: The use of drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs) and antibiotics, for at least 2 consecutive days, was recorded.

• Perceived stress: The perceived stress was assessed using the Perceived Stress Scale (PSS). A PSS score >13 was defined as moderate to high perceived stress [10].

• Recent travel: Any travel undertaken within the past 4 weeks was documented to evaluate potential exposure to new environmental factors, dietary changes, and unfamiliar pathogens.

• Acute unaccustomed physical activity/exercise: This was defined as physical activity that was new or significantly different from an individual’s usual routine. This involved a sudden increase in the intensity, duration, or type of exercise, which the body had not yet adapted to and could act as a physical stressor [11].

4. Treatment

All patients were treated with intravenous hydrocortisone (100 mg every 6 hours), in addition to correction of fluid and electrolyte balance, enteral nutrition, and prophylaxis against venous thromboembolism. Clinical assessments (including total number of stools with blood) were performed daily until discharge.

5. Outcomes

The assessed outcomes included characterization of clinical profile of patients presenting with ASUC and corticosteroid failure (defined as need for colectomy or use of rescue medical therapy such as infliximab, cyclosporine, or tofacitinib during the index hospitalization).

6. Statistical Analysis

Descriptive statistics were used to summarize patient demographics, baseline characteristics, and clinical profiles. Baseline data were reported as frequencies with percentages or median (interquartile range, IQR), as appropriate. The Kolmogorov-Smirnov test was applied to assess the normality of the data distribution. Multivariate logistic regression analysis was performed to identify independent predictors of response to IVCS during the index hospitalization. Variables with a P-value <0.10 in univariate analysis were included in the initial multivariate model. Backward elimination was employed to refine the model, sequentially removing variables with the highest P-values until only those with P<0.05 remained. The adjusted odds ratios and corresponding 95% confidence intervals were reported for the final model. All analyses were conducted using SPSS version 26.0 (IBM Corp., Armonk, NY, USA).

RESULTS

1. Patient and Disease Characteristics

A total of 145 patients (median age 36 years, IQR 26–48.5 years, 63 [43.44%] females) were included. The majority of patients had left-sided colitis (n =77, 53.10%), followed by pancolitis (n=52, 35.86%), and proctitis (n=16, 11.03%). The median disease duration was 1 year (IQR, 0.5–3 years), with most of the patients presenting with ASUC within the first year of diagnosis of UC. Eighteen patients (12.41%) had their index presentation of UC as ASUC (Table 1).

2. Clinical Presentation

At the time of hospitalization, the majority of patients (n=130, 89.65%) had been symptomatic for ≥7 days. Along with experiencing 6 or more stools with blood per day, 71 patients (48.96%) had one, 51 patients (35.17%) had two, 17 patients had three (11.72%), and 6 patients (4.13%) had four additional TW criteria. The median UCEIS score was 5 (IQR, 4–6) and 33 patients (22.75%) had deep ulcers on endoscopic examination. The ADMIT-ASC score ≥3, ACE index of 3, and ASUC score ≥2 was observed in 16 (11.03%), 18 (12.41%), and 42 (28.96%) patients, respectively. The median levels of hemoglobin, albumin, and CRP were 9.90 g/dL (IQR, 8.55–11.60 g/dL), 3.22 g/L (IQR, 2.52–3.70 g/L), and 29.28 mg/L (IQR, 9.39–78.16 mg/L), respectively (Table 2). All patients underwent nutritional screening and assessment upon hospitalization. A MUST score of ≥2 was observed in 76 patients (52.41%). The median body mass index was 20.70 kg/m² (IQR, 17.81–23.89 kg/m²) and median handgrip strength was 15 kg (IQR, 15–21.50 kg).

3. Probable Precipitants of ASUC

The probable precipitants of ASUC were classified into infectious and non-infectious categories. Among infectious causes, CDI was observed in 19 patients (13.10%), and cytomegalovirus infection was detected in 8 patients (5.51%). Additionally, 2 patients (1.37%) had urinary tract infections. In the non-infectious category, poor compliance to prescribed treatment regimens was noted in 43 patients (29.65%). Recent consumption of NSAIDs and antibiotics within 4 weeks prior to hospitalization was reported by 15 patients (10.34%) and 35 patients (24.13%), respectively. Thirty-two patients (22.06%) reported experiencing symptoms indicative of high perceived stress within the 4-week period preceding their ASUC onset. Other identified precipitants included recent travel (30 patients, 20.68%) and engagement in intense, unaccustomed physical exercise (14 patients, 8.27%). Specifically, the acute exercises included unaccustomed dancing, lifting heavy weights in gyms, fields, or farms, and operating or driving a tractor on rough terrains, such as farm fields.

4. Corticosteroid Failure

Corticosteroid failure was seen in 40 patients (27.58%). On multivariate analysis, higher stool frequency at hospitalization, ACE index ≥2, and CDI were associated with non-response to corticosteroids (Supplementary Table 1). Twenty-nine patients (20%) received medical rescue therapy, with 14 (48.27%), 6 (20.68%), and 9 (31.03%) patients receiving infliximab, cyclosporine A, and tofacitinib, respectively. Four patients (13.79%) underwent colectomy for corticosteroid refractoriness and frank bleeding per rectum. Another 3 patients underwent colectomy after failure of the medical rescue therapy (infliximab, n=2; cyclosporine, n=1) (Fig. 1). Among the patients who received rescue therapy or underwent colectomy, 7 (24.13%) had an ADMIT-ASC score of ≥3, 5 (17.24%) had an ACE index of 3, and 6 (20.68%) had an ASUC score of ≥2. Three patients (2.06%) died during the index hospitalization, all due to post colectomy sepsis and multiorgan failure. The distribution of scores of predictive indices (ADMIT-ASC, ACE, and ASUC score) are summarized in Fig. 2.

DISCUSSION

ASUC represents a medical emergency requiring prompt recognition, urgent hospitalization, and timely intervention to optimize patient outcomes. In this prospective analysis of 145 ASUC cases, the median age was 36 years, with a slight male predominance. Most patients presented with left-sided colitis. Although ASUC is frequently associated with pancolitis, our findings align with the disease patterns prevalent in India and recent studies reporting left-sided colitis as the most common disease location [12-14]. Pancolitis, characterized by extensive inflammation, is traditionally considered to present a greater disease burden compared to more localized forms of UC, such as left-sided colitis or proctitis [15]. However, in our study, two-thirds of patients had disease limited to the left colon. Interestingly, 11% of our patients had disease limited only to rectum. These findings suggest that disease severity is independent of disease extent, and even patients with limited disease, such as proctitis, are at risk of developing ASUC.

The majority of patients (60%) in our study had no prior history of hospitalizations for UC flares, despite two-thirds having received corticosteroids in the past. Additionally, 60% of patients were diagnosed with UC within 1 year of their presentation with ASUC, a figure double that reported in the earlier literature [16]. This suggests the potential existence of inherently severe subgroup, possibly driven by genetic and environmental predispositions, although the precise etiology remains elusive. Approximately one-third of the cohort had prior exposure to biologics and small molecules, reflecting the evolving ASUC treatment landscape and contemporary clinical practices [12,13,17-20].

The common precipitants of ASUC flares included poor treatment compliance (30%), the use of antibiotics (24%), high perceived stress (22%), travel (21%), NSAIDs (10%), and acute unaccustomed exercise (8%). Poor compliance to therapy was a major factor precipitating ASUC. Counseling patients on the importance of strict compliance to therapy is crucial, as it can prevent flares and reduce the risk of ASUC. The widespread and continuous use of over-the-counter antibiotics and NSAIDs may precipitate UC flares through mechanisms such as intestinal barrier disruption and gut microbial dysbiosis. Acute psychosocial stressors are known to exacerbate ASUC by inducing adrenal insufficiency, triggering systemic and mucosal proinflammatory responses, and impairing the healing phase of ASUC [21-23]. Acute exercise has variable effects on gut microbiota and metabolites. Studies indicate that acute exercise influences gut microbial metabolic activity, potentially affecting host health [24]. We hypothesize that acute unaccustomed exercise, via modulation of the gut microbial activity and variations in the abdominal pressures, may be a possible trigger of ASUC. CDI was present in 19 patients (13.10%). This prevalence is similar to the previous studies from the developed countries but higher than that previously reported from India. All patients with ASUC should, therefore, be evaluated for concomitant CDI [25-28].

One-fourth of the patients were non-responders to IVCS. Of these non-responders, 20% of the patients did not receive rescue therapy during the index hospitalization. Potential reasons for this include inhibitory costs, especially in the absence of universal healthcare insurance, requiring patients to pay out-of-pocket, and concerns about the increased risk of infections, particularly reactivation of tuberculosis associated with infliximab in countries like India with high burden of tuberculosis. While emerging data support the use of tofacitinib in ASUC and the availability of cost-effective generic formulations makes it an attractive option for rescue therapy, further experience is needed [29]. It is important to note that the study, spanning nearly 5 years, coincided with a significant transition in clinical practice. During the initial 2 years, patients requiring rescue therapy were primarily managed with infliximab or cyclosporine. In the latter half of the study, however, the introduction of generic tofacitinib in India led to its use as rescue therapy among non-responders, especially in cases where infliximab was unaffordable. Additionally, as reported, 7 patients did not receive any rescue therapy despite being non-responsive to IVCS. These cases occurred during the early years of the study when treatment options were limited due to the high cost of infliximab, contraindications to cyclosporine, or patients’ refusal to consent to colectomy. Nonetheless, these observations underscore the importance of policymakers addressing region-specific challenges, especially in resource-limited settings. Also, only approximately 5% of patients required a colectomy during the index admission. The mortality reported in the current study is higher than that reported in the contemporary literature [30]. Three patients died in the current study during index admission, all in the post colectomy period due to sepsis and multiorgan failure. However, the 30-day post colectomy mortality in emergency surgeries in UC has been reported in up to 5% of patients, consistent with the observations in the current study [29].

Interestingly, only 50% of the patients in our study had elevated CRP levels ( ≥30 mg/L); however, when the threshold was lowered to 12 mg/L, this proportion increased to 70% [31]. CRP-based indices like ADMIT-ASC and ACE have been demonstrated to predict non-response to IVCS. However, these scores need to be evaluated prospectively, especially in populations with lower CRP levels, where their performance is expected to be suboptimal [5,6]. This highlights the unmet need of either ethnicity specific predictors of response or possibly lower the current cutoff values of CRP to enhance the diagnostic accuracy of predictive indices [31-33].

A comparison of the ASUC spectrum in the present study with historical cohorts worldwide reveals stability in the demographic profile, including age at hospitalization and sex distribution, over time. Notably, the proportion of patients presenting with ASUC as an initial manifestation has decreased from approximately 25% to 12%, likely reflecting advancements in diagnostics and early disease management. With the introduction of immunosuppressants and later biologics, the therapeutic landscape of ASUC has evolved; patients are now often pre-exposed to these agents before development of ASUC. However, despite these developments, the proportion of patients requiring oral corticosteroids has remained unchanged over time. Also, the rate of non-response to IVCS has remained static and not improved, even with prior exposure to immunosuppressants and biologics. A significant shift, however, is observed in the reduced necessity for emergency colectomy. In earlier cohorts, colectomy rates were high due to limited therapeutic options, as steroids were the primary treatment modality, with biologics and other advanced therapies unavailable. The relatively low percentage of colectomy in the recent ASUC cohorts, compared to the historical cohorts, reflects a shift in the management paradigm, where rescue medical treatments have minimized the need for colectomy during initial hospitalizations [34]. Overall, the spectrum of ASUC has transitioned from a largely surgically managed condition to a medically manageable one, though it remains severe and necessitates immediate, aggressive intervention (Table 3) [25,34-43].

The strengths of the study include a comprehensive real-world assessment of the disease spectrum in patients with ASUC. To the authors’ knowledge, this is the first study focused on the disease spectrum in the era of biologics and small molecules, including evaluation of possible precipitants, in patients presenting with ASUC. The data were collected prospectively, adding robustness to the findings. However, recruitment of patients from a single-center limits the generalizability of the findings.

In conclusion, our study provides valuable insights into the spectrum of ASUC. Common precipitants, such as poor adherence to treatment, antibiotic and NSAID use, and acute stressors, were significant triggers for ASUC flares. Patient demographics, disease characteristics, prior corticosteroid use, clinical presentation, and response to IVCS have remained largely consistent across both the pre-biologic and biologic eras, suggesting an incomplete understanding of underlying disease mechanisms. However, with the introduction of biologics and small molecules as rescue therapies, the colectomy rate during index hospitalization has decreased over time.

NOTES

Funding Source

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

Sood A is on the advisory board of Janssen Pharmaceuticals (Asia-Pacific) and received honorarium for speaker events from Pfizer India and Takeda India; an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. The remaining authors disclose no conflicts.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Author Contributions

Conceptualization: Singh A, Midha V, Sood A. Data curation: Luthra M, Singh D, Jain D. Formal analysis: Bhardwaj A, Sharma R, Singh A. Investigation: Singh A, Luthra M, Bhardwaj A, Sharma R, Mahajan R. Methodology: Singh A, Mahajan R, Sood A. Project administration: Sood A, Midha V. Resources: Sood A, Singh A, Bhardwaj A. Software: Sharma R. Supervision: Midha V, Sood A. Validation: Sood A, Midha V, Singh A. Visualization: Singh A, Bhardwaj A, Sharma R, Luthra M. Writing - original draft: Singh A, Bhardwaj A, Mahajan R, Sharma R. Writing – review & editing: Sood A, Midha V, Singh A, Goyal O, Mehta V, Kaur K, Gupta YK. Approval of final manuscript: all authors.

Supplementary Material

Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

Supplementary Table 1.

Predictors of Response to Intravenous Corticosteroids in the Current Cohort (n=145)

ir-2024-00189-Supplementary-Table-1.pdf

Fig. 1.

Flow of patients.

Fig. 2.

The distribution of scores of predictive indices (ADMIT-ASC, ACE, and ASUC score), stratified according to the response or non-response to intravenous corticosteroids during index hospitalization. The numbers added as data labels, indicate the number of patients. ADMIT-ASC, admission model for intensification of therapy in acute severe colitis; ACE index, albumin, CRP, endoscopy index; ASUC, acute severe ulcerative colitis.

Table 1.

Baseline Patient and Disease Characteristics

Characteristic	Value (n = 145)
Age (yr)	36.0 (26.0–48.5)
Age at diagnosis (yr)	32.0 (23.0–45.0)
Female sex	63 (43.44)
Smoking	4 (2.75)
Disease extent
Proctitis	16 (11.03)
Left-sided colitis	77 (53.10)
Pancolitis	52 (35.86)
Disease duration	1.0 (0.5–3.0)
≤ 1 yr	91 (62.75)
> 1 yr	54 (37.24)
Index presentation as ASUC	18 (12.41)
Previous flares requiring hospitalization
0	88 (60.68)
1	26 (17.93)
2	16 (11.03)
≥3	15 (10.34)
Previous medications
5-Aminosalicylates	125 (86.20)
Corticosteroids	96 (66.20)
Thiopurines	33 (22.75)
Tofacitinib	33 (22.75)
Anti-TNFs	16 (11.03)
Anti-integrins	6 (4.13)

Values are presented as median (interquartile range) or number (%).

ASUC, acute severe ulcerative colitis; TNF, tumor necrosis factor.

Table 2.

Characteristics of Current Episode of ASUC

Variable	Value (n = 145)
Disease characteristics
No. of stools with blood	8 (6–10)
No. of patients with additional Truelove and Witts criteria
Temperature > 37.8°C	10 (6.89)
Heart rate ≥ 90/min	80 (55.17)
Hemoglobin < 10.5 g/dL	86 (59.31)
CRP ≥ 30 mg/L	72 (49.65)
No. of additional Truelove and Witts criteria
1	71 (48.96)
2	51 (35.17)
3	17 (11.72)
4	6 (4.13)
CRP ≥ 12 mg/L	102 (70.34)
ADMIT-ASC
0	6 (4.13)
1	80 (55.17)
2	43 (29.65)
≥3	16 (11.03)
ACE index
0	23 (15.86)
1	58 (40.00)
2	46 (31.72)
3	18 (12.41)
ASUC score
0	43 (29.65)
1	60 (41.37)
2	38 (26.20)
3	4 (2.75)
Duration of symptoms at the time of presentation
< 7 day	15 (10.35)
≥ 7 day	130 (89.65)
Nutritional assessment
MUST ≥ 2	76 (52.41)
BMI (kg/m²)	20.70 (17.81–23.89)
Hand grip strength (kg)	15.00 (15.00–21.50)
Possible precipitants of acute exacerbation of ulcerative colitis
Infectious causes
Clostridioides difficile infection^a	19 (13.10)
Cytomegalovirus infection	8 (5.51)
Non-infectious causes^b
Consumption of nonsteroidal anti-inflammatory drugs	15 (10.34)
Consumption of antibiotics	35 (24.13)
High perceived stress	32 (22.06)
Travel	30 (20.68)
Acute unaccustomed exercise	14 (8.27)
Poor compliance to treatment	43 (29.65)
No identifiable precipitating factor	49 (33.79)
Investigations (baseline)
Hemoglobin (g/dL)	9.90 (8.55–11.60)
Neutrophil lymphocyte ratio	3.31 (1.80–5.40)
Neutrophil percentage albumin ratio	20.74 (16.67–26.97)
Albumin (g/dL)	3.22 (2.52–3.70)
CRP (mg/L)	29.28 (9.39–78.16)
CRP albumin ratio	9.49 (3.30–29.33)
UCEIS	5 (4–6)
Deep ulcers on endoscopy	33 (22.75)
Hospital stay (days)	7 (5–10)

Values are presented as median (interquartile range) or number (%).

^a One patient had both C. difficile and cytomegalovirus infection.

^b Within 4 weeks of onset of symptoms, >1 probable precipitating factors observed in 43 patients.

CRP, C-reactive protein; ADMIT-ASC, admission model for intensification of therapy in acute severe colitis; ACE index, albumin, CRP, endoscopy index; ASUC, acute severe ulcerative colitis; MUST, malnutrition universal screening tool; BMI, body mass index; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.

Table 3.

Comparative Analysis of Key Cohort Studies Reporting the Spectrum of ASUC

Variable	Current study	Chaaban et al. [35]	Mundhra et al. [25]	Adams et al. [36]	Corte et al. [37]	Festa et al. [38]^f	Mokhele et al. [39]	Patrick et al. [40]	Lee et al. [41]	Benazzato et al. [42]	Travis et al. [43]	Dinesen et al. [34]
Study sample	145	94	153	131	89	337	98	200	99	67	49	186
Time frame	2020–2024	2018–2021	2016–2021	2015–2019	2010–2012	2005–2017	2003–2013	2000–2014	1999–2005	1996–2001	1992–1993	1950–2007
Country of origin	India	USA	India	UK	Australia	Italy	South Africa	Australia	South Korea	Italy	UK	UK
Age (yr)	36 (26–48.5)	33.5 (27.5–47)	34.9 ± 12.2	44.6 (16.4–79.6)^c	34 (16, 84)	38 (25–50)	43.2 ± 15.5	36.24 ± 16.56ⁱ	38 (14, 72)	45 ± 19^d	45.9 ± 15.3	35.8 (1, 83)^o
Age (yr)				40.6 (16.7–74.3)^d				40.45±16.17^j		44±14^c
Female sex	63 (43.4)	44 (46.8)	67 (43.8)	76 (58.0)	41 (46.1)	141 (41.8)	61 (62.2)	103 (51.5)	53 (53.5)	23 (34.3)	23 (46.9)	86 (46.2)
Smoking (current or past)	4 (2.7)	37 (39.4)	6 (3.9)	-	-	60 (17.8)^g	52 (53.1)	84 (42.0)	32 (32.3)		-	75 (40.3)
Disease extent
Proctitis	16 (11.0)	-	-	-	-	-	-		-	-	-	40 (21.5)
Left-sided colitis	77 (53.1)	-	50 (32.7)	-	-	82 (24.3)	-	64 (32.0)^k	3 (3.1)	35 (52.2)	17 (34.7)	91 (48.9)
Pancolitis	52 (35.8)	-	103 (67.3)	-	-	255 (75.7)	-	135 (67.5)	96 (96.9)	32 (47.8)	32 (65.3)	55 (29.6)
Disease duration (yr)	1 (0.5–3)	3.5 (1–11)	36 (16–55.5)^a	1.5 (0.05–7.0)^c	10 (0, 647)^a	2.6 (0.3–9)	30 (6–106)^a	2 ± 7.3ⁱ	15.0 (0, 198.9)^a	7.6 ± 7^d	-	-
Disease duration (yr)				0.8 (0.0–7.0)^d				1±3.5^j		5.0±3^c
Index presentation as ASUC	18 (12.4)	-	-	38 (29.0)	25 (28.1)	-	17 (17.3)	51 (25.5)	-	5 (7.5)	16 (32.6)	63 (33.8)
Previous medications
5-Aminosalicylates	125 (86.2)	-	-	87 (66.4)	53 (59.5)	-	65 (66.3)	80 (40.0)	-	-	44 (89.8)	-
Thiopurines	33 (22.7)	-	72 (47.1)	42 (32.1)	17 (19.1)	69 (20.5)	24 (24.5)	56 (28.0)	-	-	-	-
Tofacitinib	33 (22.7)	-	-	1 (0.7)	-	-	-	-	-	-	-	-
Biologics	22 (15.2)	48 (51.1)	10 (6.5)	36 (27.5)	12 (13.5)	34 (10.1)	-	-	-	-	-	-
Previous corticosteroids	96 (66.2)	-	98 (63.4)	-	23 (25.8)^e	214 (63.5)	40 (40.8)	97 (48.5)	-	-	-	-
Stool frequency at admission	8 (6-10)	-	10 (8–14)	11 (10.0–14.5)^c	12 (6, 25)	-	-	-	-	10 ± 4^d	8 ± 2	-
Stool frequency at admission				10 (8–13)^d						11±3^c
No. of patients with additional Truelove and Witts criteria
Temperature > 37.8°C	10 (6.9)	-	13 (8.4)	-	-	-	-	-	15 (15.2)	-	-	-
Heart rate ≥ 90/min	80 (55.2)	-	-	-	-	-	-	-	77 (77.8)	-	-	-
Hemoglobin < 10.5 g/dL	86 (59.3)	-	-	-	-	-	-	54 (27.0)	47 (47.5)	-	-	-
CRP ≥ 30 mg/L	72 (49.6)	-	-	-	-	-	-	-	62 (62.6)^m	-	-	-
No. of additional Truelove and Witts criteria
1	71 (48.9)	-	9 (5.9)	40 (30.5)	38 (42.7)	-	-	-	-	-	-	81 (43.5)^p
2	51 (35.2)	-	62 (40.5)	65 (49.6)	37 (41.6)	-	-	-	-	-	-	59 (31.7)^p
3	17 (11.7)	-	73 (47.7)	25 (19.1)	12 (13.5)	-	-	-	-	-	-	39 (21.0)^p
4	6 (4.1)	-	9 (5.9)	1 (0.7)	2 (2.2)	-	-	-	-	-	-	7 (3.8)^p
ADMIT-ASC
0	6 (4.1)	-	-	3 (2.3)	-	-	-	-	-	-	-	-
1	80 (55.2)	-	-	60 (45.8)	-	-	-	-	-	-	-	-
2	43 (29.6)	-	-	40 (30.5)	-	-	-	-	-	-	-	-
≥3	16 (11.0)	-	-	28 (21.4)	-	-	-	-	-	-	-	-
CDI	19 (13.1)	-	1 (0.6)	-	-	-	-	-	-	-	-	-
Positive CMV IHC	8 (5.5)	-	14 (9.2)	-	-	-	-	-	-	-	-	-
Prior antibiotic use	53 (36.5)	-	34 (22.2)		-	-	-	-	-	-	-	-
Prior NSAID use	50 (34.5)	-	6 (3.9)^b		-	-	-	-	-	-	-	-
Hemoglobin (g/dL)	9.9 (8.5–11.6)	-	9.56 ± 2.2	12.3 (11.1–13.4)^c	-	10.3 (9–11.8)	12 (10.8–13.2)	-	10.7 ± 2.1	11.6 ± 2.1^d	11.8 ± 2.4	-
Hemoglobin (g/dL)				12.9 (10.9–13.8)^d						10.8±1.9^c
CRP (mg/L)	29.3 (9.4–78.2)	-	33 (15.1–72.4)	101 (55.7–147.7)^c	-	30 (15–55.2)	60 (22–51)	-	62.8 ± 53.2	48.3 ± 47.5^d	78 ± 81 -
CRP (mg/L)				43.4 (23.8–72.9)^d						97.3 ± 110^c
Albumin (g/dL)	3.2 (2.5–3.7)	-	3.0 ± 0.7	2.9 (2.5–3.2)^c	-	-	3.4 (2.2–4.1)	-	2.90 ± 0.6	3.01 ± 0.72^d	-	-
Albumin (g/dL)				3.3 (2.9–3.5)^d						2.64 ± 0.62^c
UCEIS	5 (4–6)	-	5 (5–6)		5 (3, 8)	-	-	-	-	-	-	-
Medical rescue therapy	29 (20.0)	54 (57.4)	35 (22.9)	71 (54.2)	36 (40.4)	-	-	-	0	25 (37.3)	14 (28.6)	29 (15.6)^p
Colectomy during index hospitalization	4 (2.8)	11 (11.7)	22 (14.4)	19 (14.5)	9 (10.1)	-	25 (25.5)	62 (31)^l	16 (16.2)	14 (20.9)	15 (30.6)	37 (19.9)^p
Mortality	3 (2.1)	-	-	-	0	3 (0.9)^h	0	-	0	0	1 (2.04)ⁿ	0

Values are presented as mean±standard deviation, median (interquartile range), median (min, max), or number (%).

^a Duration in months.

^b Within 60 days.

^c Steroid non-responder.

^d Steroid responder.

^e Usage within 1 year.

^f Data reported for the patients who avoided early colectomy.

^g Active smoking only.

^h At a median of 46 months.

ⁱ Did not undergo colectomy.

^j Undergo colectomy.

^k Includes proctitis.

^l Assessed at 30 days.

^m Reports erythrocyte sedimentation rate >30 mm/hr.

ⁿ Five months after colectomy due to myocardial infarction.

^o At diagnosis.

^p For first admission only.

ASUC, acute severe ulcerative colitis; CRP, C-reactive protein; ADMIT-ASC, admission model for intensification of therapy in acute severe colitis; CDI, Clostridioides difficile infection; CMV, cytomegalovirus; IHC, immunohistochemistry; NSAID, nonsteroidal anti-inflammatory drugs; UCEIS, Ulcerative Colitis Endoscopic Index of Severity; - (hyphen), not reported.

REFERENCES

1. Holvoet T, Lobaton T, Hindryckx P. Optimal management of acute severe ulcerative colitis (ASUC): challenges and solutions. Clin Exp Gastroenterol 2021;14:71–81.Article PubMed PMC PDF
2. Honap S, Jairath V, Sands BE, Dulai PS, Danese S, Peyrin-Biroulet L. Acute severe ulcerative colitis trials: the past, the present and the future. Gut 2024;73:1763–1773.Article PubMed PMC
3. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041–1048.PubMed PMC
4. Singh A, Goyal MK, Midha V, et al. Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial. Am J Gastroenterol 2024;119:1365–1372.Article PubMed
5. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535–542.Article PubMed PMC
6. Adams A, Gupta V, Mohsen W, et al. OFR-10 Admission model for intensification of therapy in acute severe colitis (ADMITASC). Gut 2021;70(Suppl 4): A4–A5.Article
7. Grant RK, Jones GR, Plevris N, et al. The ACE (albumin, CRP and endoscopy) index in acute colitis: a simple clinical index on admission that predicts outcome in patients with acute ulcerative colitis. Inflamm Bowel Dis 2021;27:451–457.Article PubMed PDF
8. Deloshaan S, Pradeep KR, Dheeraj S, et al. P069 Admission steroid use, serum albumin and endoscopic severity predict intravenous steroid failure in patients with acute severe ulcerative colitis. Am J Gastroenterol 2020;115(Suppl 1): S18.Article
9. Chan AH, Horne R, Hankins M, Chisari C. The Medication Adherence Report Scale: a measurement tool for eliciting patients’ reports of nonadherence. Br J Clin Pharmacol 2020;86:1281–1288.Article PubMed PMC PDF
10. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983;24:385–396.Article PubMed
11. Chan D, Robbins H, Rogers S, Clark S, Poullis A. Inflammatory bowel disease and exercise: results of a Crohn’s and Colitis UK survey. Frontline Gastroenterol 2014;5:44–48.Article PubMed PMC
12. Choy MC, Li Wai Suen CF, Con D, et al. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an openlabel, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 2024;9:981–996.Article PubMed
13. García MJ, Riestra S, Amiot A, et al. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study). Aliment Pharmacol Ther 2024;59:1248–1259.Article PubMed
14. Sood A, Kaur K, Mahajan R, et al. Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry. Intest Res 2021;19:206–216.Article PubMed PMC PDF
15. Rowan CR, Cullen G, Mulcahy HE, et al. DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a simple method to quantify inflammatory burden in ulcerative colitis. J Crohns Colitis 2019;13:1365–1371.Article PubMed PDF
16. Angkeow J, Rothman A, Chaaban L, Paul N, Melia J. Systematic review: outcome prediction in acute severe ulcerative colitis. Gastro Hep Adv 2023;3:260–270.Article PubMed PMC
17. Walch A, Meshkat M, Vogelsang H, et al. Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. J Crohns Colitis 2010;4:398–404.Article PubMed
18. Naves JE, Llaó J, Ruiz-Cerulla A, et al. Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks. Inflamm Bowel Dis 2014;20:1375–1381.Article PubMed
19. Mocciaro F, Renna S, Orlando A, et al. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis 2012;6:681–686.Article PubMed
20. Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2018;67:237–243.Article PubMed
21. Reber SO, Obermeier F, Straub RH, Falk W, Neumann ID. Chronic intermittent psychosocial stress (social defeat/overcrowding) in mice increases the severity of an acute DSS-induced colitis and impairs regeneration. Endocrinology 2006;147:4968–4976.Article PubMed
22. Mawdsley JE, Macey MG, Feakins RM, Langmead L, Rampton DS. The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology 2006;131:410–419.Article PubMed
23. Engler H, Elsenbruch S, Rebernik L, et al. Stress burden and neuroendocrine regulation of cytokine production in patients with ulcerative colitis in remission. Psychoneuroendocrinology 2018;98:101–107.Article PubMed
24. Grosicki GJ, Langan SP, Bagley JR, et al. Gut check: unveiling the influence of acute exercise on the gut microbiota. Exp Physiol 2023;108:1466–1480.Article PubMed PMC
25. Mundhra S, Thomas D, Jain S, et al. Low prevalence of Clostridioides difficile infection in acute severe ulcerative colitis: a retrospective cohort study from northern India. Indian J Gastroenterol 2023;42:411–417.Article PubMed PDF
26. Dalal RS, Allegretti JR. Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease. Curr Opin Gastroenterol 2021;37:336–343.Article PubMed PMC
27. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:1443–1450.Article PubMed
28. Sokol H, Lalande V, Landman C, et al. Clostridium difficile infection in acute flares of inflammatory bowel disease: a prospective study. Dig Liver Dis 2017;49:643–646.Article PubMed
29. Tøttrup A, Erichsen R, Sværke C, Laurberg S, Srensen HT. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. BMJ Open 2012;2:e000823.Article PubMed PMC
30. Dong C, Metzger M, Holsbø E, Perduca V, Carbonnel F. Systematic review with meta-analysis: mortality in acute severe ulcerative colitis. Aliment Pharmacol Ther 2020;51:8–33.Article PubMed PDF
31. Croft A, Lord A, Radford-Smith G. Markers of systemic inflammation in acute attacks of ulcerative colitis: what level of C-reactive protein constitutes severe colitis? J Crohns Colitis 2022;16:1089–1096.Article PubMed PMC PDF
32. Velez DR, Menon R, Thorsen P, et al. Ethnic differences in interleukin 6 (IL-6) and IL6 receptor genes in spontaneous preterm birth and effects on amniotic fluid protein levels. Ann Hum Genet 2007;71(Pt 5): 586–600.Article PubMed
33. Gan GG, Subramaniam R, Lian LH, Nadarajan V. Ethnic variation in interleukin-6 -174 (g/c) polymorphism in the Malaysian population. Balkan J Med Genet 2013;16:53–58.Article PubMed PMC
34. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010;4:431–437.Article PubMed
35. Chaaban L, Cohen B, Cross RK, et al. Predicting outcomes in hospitalized patients with acute severe ulcerative colitis in a prospective multicenter cohort. Inflamm Bowel Dis 2024;Oct 9 . https://doi.org/10.1093/ibd/izae193.Article
36. Adams A, Gupta V, Mohsen W, et al. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut 2023;72:433–442.Article PubMed
37. Corte C, Fernandopulle N, Catuneanu AM, et al. Association between the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis 2015;9:376–381.Article PubMed
38. Festa S, Scribano ML, Pugliese D, et al. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: a multicentre cohort study. United European Gastroenterol J 2021;9:507–516.Article PubMed PMC PDF
39. Mokhele NN, Thomson SR, Watermeyer GA. Predictors of emergency colectomy in patients admitted with acute severe ulcerative colitis. S Afr J Surg 2017;55:20–26.
40. Patrick D, Doecke J, Irwin J, et al. The effect of pre-admission immunosuppression on colectomy rates in acute severe ulcerative colitis. Therap Adv Gastroenterol 2018;11:1756284818809789.Article PubMed PMC PDF
41. Lee HS, Yang SK, Soh JS, et al. Short- and long-term outcomes of acute severe ulcerative colitis in Korea: the 1999-2005 cohort. Inflamm Bowel Dis 2015;21:1825–1831.PubMed
42. Benazzato L, D’Incà R, Grigoletto F, et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004;36:461–466.Article PubMed
43. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905–910.Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India

DOI: https://doi.org/10.5217/ir.2024.00189

XML Download

Figure

Related articles

Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India

Fig. 1. Flow of patients.

Fig. 2. The distribution of scores of predictive indices (ADMIT-ASC, ACE, and ASUC score), stratified according to the response or non-response to intravenous corticosteroids during index hospitalization. The numbers added as data labels, indicate the number of patients. ADMIT-ASC, admission model for intensification of therapy in acute severe colitis; ACE index, albumin, CRP, endoscopy index; ASUC, acute severe ulcerative colitis.

Fig. 1.

Fig. 2.

Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India

Characteristic	Value (n = 145)
Age (yr)	36.0 (26.0–48.5)
Age at diagnosis (yr)	32.0 (23.0–45.0)
Female sex	63 (43.44)
Smoking	4 (2.75)
Disease extent
Proctitis	16 (11.03)
Left-sided colitis	77 (53.10)
Pancolitis	52 (35.86)
Disease duration	1.0 (0.5–3.0)
≤ 1 yr	91 (62.75)
> 1 yr	54 (37.24)
Index presentation as ASUC	18 (12.41)
Previous flares requiring hospitalization
0	88 (60.68)
1	26 (17.93)
2	16 (11.03)
≥3	15 (10.34)
Previous medications
5-Aminosalicylates	125 (86.20)
Corticosteroids	96 (66.20)
Thiopurines	33 (22.75)
Tofacitinib	33 (22.75)
Anti-TNFs	16 (11.03)
Anti-integrins	6 (4.13)

Variable	Value (n = 145)
Disease characteristics
No. of stools with blood	8 (6–10)
No. of patients with additional Truelove and Witts criteria
Temperature > 37.8°C	10 (6.89)
Heart rate ≥ 90/min	80 (55.17)
Hemoglobin < 10.5 g/dL	86 (59.31)
CRP ≥ 30 mg/L	72 (49.65)
No. of additional Truelove and Witts criteria
1	71 (48.96)
2	51 (35.17)
3	17 (11.72)
4	6 (4.13)
CRP ≥ 12 mg/L	102 (70.34)
ADMIT-ASC
0	6 (4.13)
1	80 (55.17)
2	43 (29.65)
≥3	16 (11.03)
ACE index
0	23 (15.86)
1	58 (40.00)
2	46 (31.72)
3	18 (12.41)
ASUC score
0	43 (29.65)
1	60 (41.37)
2	38 (26.20)
3	4 (2.75)
Duration of symptoms at the time of presentation
< 7 day	15 (10.35)
≥ 7 day	130 (89.65)
Nutritional assessment
MUST ≥ 2	76 (52.41)
BMI (kg/m²)	20.70 (17.81–23.89)
Hand grip strength (kg)	15.00 (15.00–21.50)
Possible precipitants of acute exacerbation of ulcerative colitis
Infectious causes
Clostridioides difficile infection^a	19 (13.10)
Cytomegalovirus infection	8 (5.51)
Non-infectious causes^b
Consumption of nonsteroidal anti-inflammatory drugs	15 (10.34)
Consumption of antibiotics	35 (24.13)
High perceived stress	32 (22.06)
Travel	30 (20.68)
Acute unaccustomed exercise	14 (8.27)
Poor compliance to treatment	43 (29.65)
No identifiable precipitating factor	49 (33.79)
Investigations (baseline)
Hemoglobin (g/dL)	9.90 (8.55–11.60)
Neutrophil lymphocyte ratio	3.31 (1.80–5.40)
Neutrophil percentage albumin ratio	20.74 (16.67–26.97)
Albumin (g/dL)	3.22 (2.52–3.70)
CRP (mg/L)	29.28 (9.39–78.16)
CRP albumin ratio	9.49 (3.30–29.33)
UCEIS	5 (4–6)
Deep ulcers on endoscopy	33 (22.75)
Hospital stay (days)	7 (5–10)

Variable	Current study	Chaaban et al. [35]	Mundhra et al. [25]	Adams et al. [36]	Corte et al. [37]	Festa et al. [38]^f	Mokhele et al. [39]	Patrick et al. [40]	Lee et al. [41]	Benazzato et al. [42]	Travis et al. [43]	Dinesen et al. [34]
Study sample	145	94	153	131	89	337	98	200	99	67	49	186
Time frame	2020–2024	2018–2021	2016–2021	2015–2019	2010–2012	2005–2017	2003–2013	2000–2014	1999–2005	1996–2001	1992–1993	1950–2007
Country of origin	India	USA	India	UK	Australia	Italy	South Africa	Australia	South Korea	Italy	UK	UK
Age (yr)	36 (26–48.5)	33.5 (27.5–47)	34.9 ± 12.2	44.6 (16.4–79.6)^c	34 (16, 84)	38 (25–50)	43.2 ± 15.5	36.24 ± 16.56ⁱ	38 (14, 72)	45 ± 19^d	45.9 ± 15.3	35.8 (1, 83)^o
Age (yr)				40.6 (16.7–74.3)^d				40.45±16.17^j		44±14^c
Female sex	63 (43.4)	44 (46.8)	67 (43.8)	76 (58.0)	41 (46.1)	141 (41.8)	61 (62.2)	103 (51.5)	53 (53.5)	23 (34.3)	23 (46.9)	86 (46.2)
Smoking (current or past)	4 (2.7)	37 (39.4)	6 (3.9)	-	-	60 (17.8)^g	52 (53.1)	84 (42.0)	32 (32.3)		-	75 (40.3)
Disease extent
Proctitis	16 (11.0)	-	-	-	-	-	-		-	-	-	40 (21.5)
Left-sided colitis	77 (53.1)	-	50 (32.7)	-	-	82 (24.3)	-	64 (32.0)^k	3 (3.1)	35 (52.2)	17 (34.7)	91 (48.9)
Pancolitis	52 (35.8)	-	103 (67.3)	-	-	255 (75.7)	-	135 (67.5)	96 (96.9)	32 (47.8)	32 (65.3)	55 (29.6)
Disease duration (yr)	1 (0.5–3)	3.5 (1–11)	36 (16–55.5)^a	1.5 (0.05–7.0)^c	10 (0, 647)^a	2.6 (0.3–9)	30 (6–106)^a	2 ± 7.3ⁱ	15.0 (0, 198.9)^a	7.6 ± 7^d	-	-
Disease duration (yr)				0.8 (0.0–7.0)^d				1±3.5^j		5.0±3^c
Index presentation as ASUC	18 (12.4)	-	-	38 (29.0)	25 (28.1)	-	17 (17.3)	51 (25.5)	-	5 (7.5)	16 (32.6)	63 (33.8)
Previous medications
5-Aminosalicylates	125 (86.2)	-	-	87 (66.4)	53 (59.5)	-	65 (66.3)	80 (40.0)	-	-	44 (89.8)	-
Thiopurines	33 (22.7)	-	72 (47.1)	42 (32.1)	17 (19.1)	69 (20.5)	24 (24.5)	56 (28.0)	-	-	-	-
Tofacitinib	33 (22.7)	-	-	1 (0.7)	-	-	-	-	-	-	-	-
Biologics	22 (15.2)	48 (51.1)	10 (6.5)	36 (27.5)	12 (13.5)	34 (10.1)	-	-	-	-	-	-
Previous corticosteroids	96 (66.2)	-	98 (63.4)	-	23 (25.8)^e	214 (63.5)	40 (40.8)	97 (48.5)	-	-	-	-
Stool frequency at admission	8 (6-10)	-	10 (8–14)	11 (10.0–14.5)^c	12 (6, 25)	-	-	-	-	10 ± 4^d	8 ± 2	-
Stool frequency at admission				10 (8–13)^d						11±3^c
No. of patients with additional Truelove and Witts criteria
Temperature > 37.8°C	10 (6.9)	-	13 (8.4)	-	-	-	-	-	15 (15.2)	-	-	-
Heart rate ≥ 90/min	80 (55.2)	-	-	-	-	-	-	-	77 (77.8)	-	-	-
Hemoglobin < 10.5 g/dL	86 (59.3)	-	-	-	-	-	-	54 (27.0)	47 (47.5)	-	-	-
CRP ≥ 30 mg/L	72 (49.6)	-	-	-	-	-	-	-	62 (62.6)^m	-	-	-
No. of additional Truelove and Witts criteria
1	71 (48.9)	-	9 (5.9)	40 (30.5)	38 (42.7)	-	-	-	-	-	-	81 (43.5)^p
2	51 (35.2)	-	62 (40.5)	65 (49.6)	37 (41.6)	-	-	-	-	-	-	59 (31.7)^p
3	17 (11.7)	-	73 (47.7)	25 (19.1)	12 (13.5)	-	-	-	-	-	-	39 (21.0)^p
4	6 (4.1)	-	9 (5.9)	1 (0.7)	2 (2.2)	-	-	-	-	-	-	7 (3.8)^p
ADMIT-ASC
0	6 (4.1)	-	-	3 (2.3)	-	-	-	-	-	-	-	-
1	80 (55.2)	-	-	60 (45.8)	-	-	-	-	-	-	-	-
2	43 (29.6)	-	-	40 (30.5)	-	-	-	-	-	-	-	-
≥3	16 (11.0)	-	-	28 (21.4)	-	-	-	-	-	-	-	-
CDI	19 (13.1)	-	1 (0.6)	-	-	-	-	-	-	-	-	-
Positive CMV IHC	8 (5.5)	-	14 (9.2)	-	-	-	-	-	-	-	-	-
Prior antibiotic use	53 (36.5)	-	34 (22.2)		-	-	-	-	-	-	-	-
Prior NSAID use	50 (34.5)	-	6 (3.9)^b		-	-	-	-	-	-	-	-
Hemoglobin (g/dL)	9.9 (8.5–11.6)	-	9.56 ± 2.2	12.3 (11.1–13.4)^c	-	10.3 (9–11.8)	12 (10.8–13.2)	-	10.7 ± 2.1	11.6 ± 2.1^d	11.8 ± 2.4	-
Hemoglobin (g/dL)				12.9 (10.9–13.8)^d						10.8±1.9^c
CRP (mg/L)	29.3 (9.4–78.2)	-	33 (15.1–72.4)	101 (55.7–147.7)^c	-	30 (15–55.2)	60 (22–51)	-	62.8 ± 53.2	48.3 ± 47.5^d	78 ± 81 -
CRP (mg/L)				43.4 (23.8–72.9)^d						97.3 ± 110^c
Albumin (g/dL)	3.2 (2.5–3.7)	-	3.0 ± 0.7	2.9 (2.5–3.2)^c	-	-	3.4 (2.2–4.1)	-	2.90 ± 0.6	3.01 ± 0.72^d	-	-
Albumin (g/dL)				3.3 (2.9–3.5)^d						2.64 ± 0.62^c
UCEIS	5 (4–6)	-	5 (5–6)		5 (3, 8)	-	-	-	-	-	-	-
Medical rescue therapy	29 (20.0)	54 (57.4)	35 (22.9)	71 (54.2)	36 (40.4)	-	-	-	0	25 (37.3)	14 (28.6)	29 (15.6)^p
Colectomy during index hospitalization	4 (2.8)	11 (11.7)	22 (14.4)	19 (14.5)	9 (10.1)	-	25 (25.5)	62 (31)^l	16 (16.2)	14 (20.9)	15 (30.6)	37 (19.9)^p
Mortality	3 (2.1)	-	-	-	0	3 (0.9)^h	0	-	0	0	1 (2.04)ⁿ	0

Table 1. Baseline Patient and Disease Characteristics

Values are presented as median (interquartile range) or number (%).

ASUC, acute severe ulcerative colitis; TNF, tumor necrosis factor.

Table 2. Characteristics of Current Episode of ASUC

Values are presented as median (interquartile range) or number (%).

One patient had both C. difficile and cytomegalovirus infection.

Within 4 weeks of onset of symptoms, >1 probable precipitating factors observed in 43 patients.

Table 3. Comparative Analysis of Key Cohort Studies Reporting the Spectrum of ASUC

Values are presented as mean±standard deviation, median (interquartile range), median (min, max), or number (%).

Duration in months.

Within 60 days.

Steroid non-responder.

Steroid responder.

Usage within 1 year.

Data reported for the patients who avoided early colectomy.

Active smoking only.

At a median of 46 months.

Did not undergo colectomy.

Undergo colectomy.

Includes proctitis.

Assessed at 30 days.

Reports erythrocyte sedimentation rate >30 mm/hr.

Five months after colectomy due to myocardial infarction.

At diagnosis.

For first admission only.